-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Novartis, Raises Price Target to $170

Benzinga·03/26/2026 17:39:54
Listen to the news
Morgan Stanley analyst Mark Purcell maintains Novartis (NYSE:NVS) with a Overweight and raises the price target from $143 to $170.